Episode
Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 1
- Podcast
- Gynecologic Oncology Update
- Published
- Sep 13, 2026
- Duration seconds
- 1726
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/gynecologic-oncology-update-612940/episodes/low-grade-serous-ovarian-cancer-5-minute-journal-club-microlearning-activity-1/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/gynecologic-oncology-update-612940/low-grade-serous-ovarian-cancer-5-minute-journal-club-microlearning-activity-1.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Rachel N Grisham, including the following topics: Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00) A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11) Current and future role of avutometinib with defactinib for LGSOC (19:23) A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37) CME information and select publications